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Chronic vertigo is a challenging problem. Currently patients
are generally treated in general practice with betahistine
(off-label use), while stronger evidence exists for the
effectiveness of vestibular rehabilitation.
Vertigo is themost common type of dizziness.1Each year around
1 in 20 people in the general population experiences vertigo.2
Around 80% of these people affected by vertigo find that it
severely impairs their daily functioning.2 Since the symptoms
of vertigo prevent many people from working, as well as
resulting in an increase in the risk of falling and a high use of
healthcare services, vertigo also represents a substantial
economic cost.2
Most cases of vertigo are caused by peripheral vestibular
disorders such as vestibular neuronitis, benign paroxysmal
positional vertigo, vestibular migraine, and Ménière’s disease.2
Initial treatment varies, depending on the most likely vestibular
disorder. Box 1 provides an overview of specific treatments for
the most common peripheral vestibular disorders.
All peripheral vestibular disorders have a distinct natural course
with a substantial chance of developing chronic vertigo4: 30-40%
of patients with vestibular neuronitis still experience vertigo
after six months, and 50% of patients will have experienced
recurrence of benign paroxysmal positional vertigo by 3-5 years
after initial diagnosis.2 4 Vertigo is defined as a false sensation
that the body or environment is moving.15Acute vertigo concerns
well defined, isolated spells with a distinct onset and offset,
whereas chronic vertigo is defined as a continuous sensation or
recurrent attacks of vertigo.16 Although a clear definition of
duration is lacking,15 chronic vertigo is often defined as
symptoms persisting for more than one month (based on the
clinical course of vestibular disorders17 and expert opinion18).
Peripheral vestibular disorders induce an important innate repair
mechanism known as vestibular compensation, which aids
functional recovery after damage to the vestibular system.19
However, there is a large inter-individual variation in the rate
and level of recovery.19 Chronic vertigo occurs when natural
vestibular compensation fails.19 Vestibular rehabilitation (see
box 2) is now considered the preferred treatment for patients
with chronic vertigo1-22 and is recommended by US,8 23 Dutch,18
and UK24 clinical practice guidelines. In spite of this guidance,
anti-vertigo drugs such as betahistine (see box 3) are commonly
prescribed, and vestibular rehabilitation is hardly used to treat
chronic vertigo. An observational study of patients with vertigo
from 13 different European countries (4294 participants) found
that betahistine was prescribed to more than two thirds of
patients with vertigo in general practice at first consultation and
was still being used six months later.25 In contrast, surveys of
general practitioners in the Netherlands (n=426)31 and UK
(n=53)32 found that only 5.8-6.8% used vestibular rehabilitation.
Recent Cochrane reviews showed moderate quality evidence
for the effectiveness of vestibular rehabilitation and weak
evidence for the effectiveness of betahistine to treat chronic
vertigo.7 33 There is therefore a need to address the discrepancy
between current clinical practice and current evidence in the
treatment of chronic vertigo.
The evidence for change
There is moderate quality evidence, partly from general practice
studies, that vestibular rehabilitation is a safe and effective
treatment for chronic vertigo (see table 1⇓). There is low quality
evidence, conducted in secondary and tertiary care populations,
that patients with chronic vertigo experience a benefit from
betahistine treatment compared with placebo (table 1⇓).
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What you need to know
• Patients with vertigo should first be treated with any specific treatment for the underlying vestibular disease
• Vestibular rehabilitation is a form of exercise therapy designed to optimise the process of vestibular compensation that is disrupted
in patients with chronic vertigo
• Patients with chronic vertigo who do not respond to disease-specific treatments should be offered vestibular rehabilitation instead of
anti-vertigo drugs
Box 1: Specific treatments for the most common peripheral vestibular disorders
Vestibular neuronitis
• There is no known curative treatment for vestibular neuronitis; evidence for the effectiveness of treatment with corticosteroids is insufficient3
• Symptomatic treatment with vestibular suppressant medications (anticholinergics, antihistamines, and benzodiazepines) and antiemetics can
be given in the acute phase of vestibular neuronitis.4 However, these drugs should not be prescribed for longer than three days5 6 because
they can be counterproductive due to suppression of vestibular compensation4
• Vestibular rehabilitation is indicated if the patient experiences chronic vertigo7
Benign paroxysmal positional vertigo (BPPV)
• Patients suspected of posterior canal BPPV should be treated initially with a canalith repositioning manoeuvre called the Epley manoeuvre.7-9
The optimal number of Epley manoeuvres is still unclear, but repetition has a beneficial effect when nystagmus persists after the first treatment10
• Vestibular rehabilitation is indicated when patients with chronic vertigo are unwilling or unable to undergo an Epley manoeuvre or experience
persisting disability after the Epley manoeuvre7 8
Vestibular migraine
• Evidence for disease-specific treatment is limited.11-13 Guidelines for the diagnosis of vestibular migraine have only recently been established,
and no intervention trials with well defined patient groups have yet been conducted. There is no well established drug that can prevent vestibular
migraine attacks12
• Familiar therapies for migraine attacks such as triptans and antiemetics can be considered, but their use is mostly based on expert opinion.11 13
Patients with vestibular migraine were not included in the 2015 Cochrane review of vestibular rehabilitation7
• Based on weak evidence, vestibular rehabilitation is advised when patients experience persistent vertigo symptoms between migraine attacks11
Ménière’s disease
• Patients suspected of Ménière’s diseases should be referred to a ENT specialist for diagnosis and treatment
• Vestibular rehabilitation is not indicated for acute vertigo attacks in Ménière’s disease, but should be offered to patients who develop persisting
vertigo symptoms7 14
Box 2: Vestibular rehabilitation
Vestibular rehabilitation is an exercise based treatment consisting of varied eye, head, and body movements designed to stimulate the
vestibular system and optimise vestibular compensation.7 The treatment is suited for all patients with vestibular dysfunction who are able to
complete a daily, low intensity exercise programme for 6-12 weeks.7-21
Box 3: Betahistine
The most prescribed anti-vertigo drug is betahistine.25 26 It is estimated that more than 130 million patients have taken betahistine since its
launch in 1968.27 This is surprising, since betahistine has no FDA approval in the US due to insufficient efficacy28 and is only registered for
the relatively rare Ménière’s disease in other countries.26-30 This discrepancy can be explained by excessive off-label use. A Canadian
observational study (50 823 patients) found off-label prescribing in 91.5% of all betahistine prescriptions.30 Off-label prescriptions are
considered “ill founded” when prescribing is not advised by clinical practice guidelines or pharmacotherapeutic handbooks. A Dutch
observational study (319 843 participants) found that 26.4% of all betahistine prescriptions were ill founded off-label.26
Sources and selection criteria
We searched Medline, PubMed, and the Cochrane Database of Systematic Reviews to identify randomised controlled trials and systematic
reviews that assessed the safety and effectiveness of vestibular rehabilitation and betahistine in the treatment of chronic vertigo. We found
two recent Cochrane reviews that investigated the effectiveness of vestibular rehabilitation (2015)7 and betahistine (2016).33 The BEMED
trial35 and an online vestibular rehabilitation trial37 were the only relevant randomised controlled trials identified that were not already included
in these Cochrane reviews.
We searched clinicaltrials.gov and WHO ICTRP and identified one relevant ongoing clinical randomised controlled trial. In this trial, online
vestibular rehabilitation, with and without guidance, is compared with usual care.38 At the moment there are no ongoing randomised controlled
trials for betahistine in the treatment of chronic vertigo.
Effectiveness of vestibular rehabilitation
A Cochrane review updated in 2015 (39 randomised controlled
trials, 2441 participants) compared vestibular rehabilitation for
unilateral peripheral vestibular dysfunction with sham exercises
or no intervention.7 Participants experienced vestibular
dysfunction from a variety of causes including vestibular
neuritis, benign paroxysmal positional vertigo, late stage
Ménière’s disease with a non-fluctuating vestibular deficit, or
a combination of peripheral vestibular disorders. Because of
heterogeneity in study design, not all studies could be pooled.
In a pooled analysis of four studies in which all patients
experienced chronic vertigo, patients assigned to vestibular
rehabilitation reported higher subjective improvement in vertigo
(odds ratio 2.67 (95% confidence interval 1.85 to 3.86), 565
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participants). There were no reported adverse effects in any of
the 39 randomised controlled trials. Three high quality trials
(589 patients) were conducted in a general practice
population.20-22
We applied the GRADE methodology and judged the overall
quality of evidence as moderate. We deemed the risk of bias
serious, since over a third of studies in the review were rated as
having a high risk of bias. There was no serious inconsistency,
indirectness, imprecision, or publication bias.We can summarise
that, based on moderate to high quality randomised controlled
trials, there is moderate evidence that vestibular rehabilitation
is a safe and effective treatment for chronic vertigo.7
Effectiveness of betahistine
Betahistine was originally developed forMénière’s disease, and
early trials were targeted at these patients. A Cochrane review
(last updated 2011, 7 randomised controlled trials, 243 patients)
that compared betahistine with placebo in patients with
Ménière’s disease concluded there was insufficient evidence to
say whether betahistine has any effect on Ménière’s disease.34
Recently, a randomised, placebo controlled trial investigated
vertigo symptoms in 211 patients with Ménière’s disease and
found no statistically significant benefit for betahistine over
placebo.35
The effectiveness of betahistine for symptoms of vertigo
(including 14 trials with patients with chronic vertigo and 3
trials with a mix of acute and chronic vertigo patients) was
examined in a Cochrane review in 2016 (17 randomised
controlled trials (including 5 unpublished industry studies),
1025 patients).33 Participants had varied neurotological
diagnoses, including Ménière’s disease, benign paroxysmal
positional vertigo, and vertigo of unknown origin. In a pooled
analysis with patients all experiencing chronic vertigo, a
statistically significant improvement in vertigo symptoms was
seen in the betahistine group compared with the placebo group
(risk ratio 1.30 (95% CI 1.05 to 1.60), 606 participants, 11
studies). Nearly all included trials had a high risk of bias with
poor reporting of methods and outcome measures. In contrast
to vestibular rehabilitation, none of these trials was conducted
in a general practice population, which limits the applicability
of these results for general practice.
Consequences of current clinical practice
Betahistine leads to substantial healthcare costs. Stopping
off-label use of betahistine in the UK alone would save over £4
000 000 a year.29 Since evidence for the most registered
indication (Ménière’s disease) is also insufficient, costs could
be decreased even further by completely stopping betahistine
prescriptions. By choosing betahistine, doctors deny other
treatments to patients that have better established evidence of
effectiveness. Different causes of peripheral vestibular disease,
such as benign paroxysmal positional vertigo and Ménière’s
disease, have a specific preferred treatment (see box 1). When
chronic vertigo develops after such disease-specific treatments,
vestibular rehabilitation should be prescribed by general
practitioners.
Barriers to change
The most important barrier to general practitioners using
vestibular rehabilitation is that they do not know how to perform
the treatment. Most patients surveyed prefer exercise based
treatment over anti-vertigo drugs.
There is limited evidence on the factors that contribute to the
current mismatch between scientific evidence and clinical
practice in the treatment of chronic vertigo. We conducted a
survey among 426 Dutch general practitioners about the use of
vestibular rehabilitation.31 The main reason for not applying
vestibular rehabilitation was that general practitioners did not
know how to perform the technique (92.4%).31 Other reasons
were that it was too time consuming (7.2%), general
practitioners had doubts about its effectiveness (6.3%), and it
was not recommended in national guidelines (4.5%). Perceived
patient pressure is a key reason that general practitioners
prescribe drugs, even though this perception often does not
match the patients’ real expectations.36 The Dutch College of
General Practitioners conducted a focus group meeting (see box
4). Patients preferred exercise based treatment over anti-vertigo
drugs, but most were offered only drug therapy by their general
practitioner. Since betahistine is generally well tolerated,
prescribing this drug could be considered an easy fix for a
difficult complaint. Compared with a straightforward
prescription of betahistine, vestibular rehabilitation may be seen
by general practitioners as a difficult and time consuming
treatment.
How should we change our practice?
Offer patients with vertigo disease-specific treatments (box 1).
Plan a follow-up consultation if symptoms do not resolve after
disease-specific treatment (see box 1). Evaluate the effect of
treatment to ascertain whether the patient has developed chronic
vertigo. Chronic vertigo is present if symptoms persist for more
than a month. There is no place for betahistine or any other
anti-vertigo drugs in the treatment of chronic vertigo: stop all
anti-vertigo drugs that the patient is using for acute vertigo (see
box 1 for indications) and offer vestibular rehabilitation to all
patients with chronic vertigo.
In a recently published trial an online vestibular rehabilitation
intervention was shown to be effective and well liked by patients
with chronic vertigo.37 Such newly developed self help methods
of vestibular rehabilitation (internet based37 or booklet based22)
help general practitioners to treat patients with vestibular
rehabilitation. For patients who needmore support, offer referral
to physiotherapists or audiologists for extra guidance.
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Box 4: How patients were involved in the creation of this article
The Dutch College of General Practitioners conducted a focus group meeting with 10 patients with vertigo in 2016 as part of the revision of
the Dutch guidelines on dizziness (in which ORM is involved). Most of these patients had experienced vertigo symptoms for more than three
months. Patients’ ages ranged from 43 to 80 years, eight were women, and disorders represented included benign paroxysmal positional
vertigo, vestibular neuronitis, and vertigo of unknown origin. These patients had consulted their general practitioner in the previous year with
vertigo complaints, usually chronic.
The aim of the focus group was to gain insight into the patients’ perspectives on vertigo treatments. According to the patients, treatment
should provide them with a sense of control over their vertigo symptoms. This was one of the reasons why all patients strongly appreciated
exercise based treatment. Even though none of the patients explicitly requested drug treatment, several patients were offered betahistine
by their general practitioner. Patients did not like taking anti-vertigo drugs. Some never even took the prescribed betahistine because they
were afraid of side effects. Only one patient received vestibular rehabilitation. This patient experienced a reduction in vertigo symptoms and
was very enthusiastic about the treatment. All patients concurred that general practitioners should at least know of the existence of vestibular
rehabilitation.
These perspectives on treating vertigo inspired us to write this article. We consulted a patient with chronic vertigo after writing this manuscript
to see if we correctly voiced the patients’ opinion. She confirmed that she, and other chronic vertigo patients generally prefer exercise based
treatment over drug therapy.
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Table
Table 1| Summary of evidence for the treatment of chronic vertigo
Summary of
quality of
evidenceNNT*
Anticipated absolute
effects (95% CI)ResultsComparatorInterventionParticipantsStudy design
Vestibular rehabilitation
Moderate quality
evidence†
5For every 1000 patients,
225 (135 to 317) more will
improve with vestibular
rehabilitation than with
control
Vertigo symptoms
reduced with vestibular
rehabilitation, odds
ratio 2.67 (95%CI 1.85
to 3.86).
Sham or no
intervention
Vestibular
rehabilitation
565 adults with different
causes of chronic vertigo
(vestibular neuronitis,
non-fluctuating Ménière’s
disease, benign paroxysmal
positional vertigo, undefined
vertigo)
Systematic review
and meta-analysis (4
randomised controlled
trials)7
Betahistine
Low quality
evidence†
8For every 1000 patients,
140 (23 to 277) more will
improve with betahistine
than with control
Vertigo symptoms
reduced with
betahistine, risk ratio
1.30 (95% CI 1.05 to
1.60).
PlaceboBetahistine in
varying doses
606 adults with different
causes of chronic vertigo
(Ménière’s disease, benign
paroxysmal positional vertigo,
undefined vertigo)
Systematic review
andmeta-analysis (11
randomised controlled
trials)33
*Number needed to treat
†Evidence judged by GRADE methodology
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